Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi SA    SAN   FR0000120578

SANOFI SA

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : Regeneron See Positive Results From Dupixent Phase 3 Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2020 | 05:19pm EDT

By Kimberly Chin

 

Sanofi SA and Regeneron Pharmaceuticals Inc. said it had positive results for an advanced trial of a treatment for patients with a chronic, allergic inflammatory disease of the esophagus.

The Phase 3 trial of Dupixent met both its co-primary endpoints, as well as important secondary endpoints, the companies said. The trial had 81 patients, ages 12 years and older, who had eosinophilic esophagitis.

The patients were able to show clinical and anatomic improvements, including the ability to swallow. Patients saw a 69% reduction in disease symptoms, as well as a 60% reduction in their esophageal eosinophilic count to a normal range, the companies said.

Eosinophilic esophagitis damages the esophagus and impairs its functions, making it difficult to swallow. It could also damage and scar the esophagus without treatment.

This was the first and only biologic to show "positive and clinically meaningful results" in an advanced trial, the companies said.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS -0.95% 598.54 Delayed Quote.59.41%
SANOFI SA -0.39% 88.52 Real-time Quote.-0.86%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI SA
06/04SANOFI : to launch 'Action 2020', a worldwide employee stock purchase plan
AQ
06/04SANOFI : Biotechnology Innovation Organization - Stopping the COVID 'Spike'
AQ
06/03Sanofi to launch “Action 2020”, a worldwide employee stock purcha..
GL
06/03SANOFI : - European Commission approves Sarclisa for adults with relapsed and re..
AQ
06/03SANOFI : - Sarclisa combination therapy demonstrated superior progression free s..
AQ
06/03SANOFI : Credit Suisse maintains a Buy rating
MD
06/02BIOCON : Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi's Fou..
AQ
06/02Sarclisa® (isatuximab) combination therapy demonstrated superior progression ..
GL
06/02European Commission approves Sarclisa® (isatuximab) for adults with relapsed ..
GL
06/02Sanofi to present oncology strategy, provide update on portfolio and emerging..
GL
More news
Financials
Sales 2020 37 440 M 42 565 M 42 565 M
Net income 2020 5 671 M 6 447 M 6 447 M
Net Debt 2020 15 150 M 17 224 M 17 224 M
P/E ratio 2020 18,6x
Yield 2020 3,61%
Capitalization 111 B 126 B 127 B
EV / Sales 2019
EV / Sales 2020 3,38x
Nbr of Employees 100 409
Free-Float 89,1%
Chart SANOFI SA
Duration : Period :
Sanofi SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI SA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 104,08 €
Last Close Price 88,85 €
Spread / Highest target 38,2%
Spread / Average Target 17,1%
Spread / Lowest Target -4,33%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Chief Medical & Digital Officer
John C. Reed EVP & Global Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI SA-0.86%126 079
JOHNSON & JOHNSON0.59%386 574
ROCHE HOLDING AG5.97%296 065
MERCK & CO., INC.-10.34%205 840
PFIZER, INC.-8.09%200 030
NOVARTIS AG-11.02%188 340